Home › Funds › Privium Fund Management B.V. › RCKT
Privium Fund Management B.V. position in RCKT
ROCKET PHARMACEUTICALS INC · Health Care
Privium Fund Management B.V. reported holding 244,146 shares of RCKT (ROCKET PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$642K, representing 0.12% of its reported portfolio and ranking #45 among its reported holdings. Privium Fund Management B.V. has disclosed RCKT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Privium Fund Management B.V.'s RCKT position evolved
Privium Fund Management B.V. first disclosed a stake in RCKT in Q3 2023 at 143,350 shares (US$2.9M). The position peaked in Q4 2023 at 233,050 shares, worth US$6.9M. Across 13 filings, Privium Fund Management B.V. increased the stake 8 time(s), trimmed it 1 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 244,146 shares valued at US$642K. Notable position changes include a 63% increase in Q4 2023 (shares fell 10% over the following quarter), a 61% trim in Q4 2025 (shares rose 2% over the following quarter), a 42% increase in Q1 2026 (shares fell 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 143.35K | $2.94M | New |
| Q4 2023 | 233.05K | $6.87M | Add |
| Q1 2024 | 235.05K | $6.33M | Add |
| Q2 2024 | 250.98K | $4.96M | Add |
| Q3 2024 | 294.80K | $5.44M | Add |
| Q4 2024 | 397.65K | $5.00M | Add |
| Q1 2025 | 432.76K | $2.89M | Add |
| Q2 2025 | 432.76K | $1.12M | Hold |
| Q3 2025 | 432.76K | $1.41M | Hold |
| Q4 2025 | 170.15K | $597.21K | Reduce |
| Q1 2026 | 242.15K | $866.88K | Add |
| Q2 2026 | 244.15K | $834.98K | Add |
| Q3 2026 | 244.15K | $642.10K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RCKT and 13F data
RCKT (ROCKET PHARMACEUTICALS INC) is a Health Care company. 15 other funds we track also report a position in RCKT — the largest reported positions include RTW INVESTMENTS, LP (US$60.5M), Newtyn Management, LLC (US$13.7M), Maverick Capital (US$13.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RCKT
- RTW INVESTMENTS, LP 17.69M sh · $60.49M · Q2 2026
- Newtyn Management, LLC 4.00M sh · $13.68M · Q2 2026
- Maverick Capital 3.92M sh · $13.42M · Q2 2026
- MAVERICK CAPITAL LTD 3.92M sh · $13.42M · Q2 2026
- Monaco Asset Management SAM 2.92M sh · $7.68M · Q3 2026
More on Privium Fund Management B.V.
FAQ
How long has Privium Fund Management B.V. held RCKT?
Privium Fund Management B.V. has disclosed RCKT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Privium Fund Management B.V.'s current position in RCKT?
As of Q3 2026, Privium Fund Management B.V. holds 244.15K shares of RCKT (ROCKET PHARMACEUTICALS INC), valued at $642.10K, representing 0.12% of its reported portfolio and ranking #45.
Has Privium Fund Management B.V. been buying or selling RCKT?
In the latest 13F filing (Q3 2026), Privium Fund Management B.V. held unchanged its position in RCKT. The position peaked in Q4 2023 at 233.05K shares.
Which other funds hold RCKT?
Other major institutional holders of RCKT include RTW INVESTMENTS, LP, Newtyn Management, LLC, Maverick Capital, among 15 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.